Treatment with IL-33 alone or the combination of IL-33 with PD-1 blockade boosted the cytotoxicity of hILC2s and anti-tumor activity in a mouse model of melanoma (Maggi et al., 2020; Jacquelot et al., 2021b). This evidence concerns the gene IL33 and melanoma.